Patients with open-angle glaucoma or ocular hypertension enrolled in APOLLO and LUNAR had combined average diurnal baseline IOPs of 26.7 mmHg in the VYZULTA® group and 26.5 mmHg in the timolol maleate 0.5% group.
Comparison of mean IOP by visit and time point (ANCOVA) –
ITT populations with last observation carried forward (pooled analysis)†‡§¶
VYZULTA® had an IOP-lowering effect of 9 mmHg from baseline vs. 7.4 mmHg for timolol maleate 0.5% (Pooled studies, month 3, 4 PM evaluation time point):
• Mean IOP was 17.77 mmHg for VYZULTA® vs. 19.1 mmHg for timolol maleate 0.5% (95% CI: -1.78 to -0.87; p<0.001)